Pancreatic cancer classification: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 164: | Line 164: | ||
|} | |} | ||
<br /> | <br />**Key | ||
CgA- Chromogranin A | |||
CgB- Chromogranin B | |||
PP- Pancreatic polypeptide | |||
*'''TNM classification for pancreatic cancer:'''<ref name="pmid22592847">{{cite journal| author=Bond-Smith G, Banga N, Hammond TM, Imber CJ| title=Pancreatic adenocarcinoma. | journal=BMJ | year= 2012 | volume= 344 | issue= | pages= e2476 | pmid=22592847 | doi=10.1136/bmj.e2476 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22592847 }} </ref> <ref name="pmid22997452">{{cite journal| author=Seufferlein T, Bachet JB, Van Cutsem E, Rougier P, ESMO Guidelines Working Group| title=Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. | journal=Ann Oncol | year= 2012 | volume= 23 Suppl 7 | issue= | pages= vii33-40 | pmid=22997452 | doi=10.1093/annonc/mds224 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22997452 }} </ref> | *'''TNM classification for pancreatic cancer:'''<ref name="pmid22592847">{{cite journal| author=Bond-Smith G, Banga N, Hammond TM, Imber CJ| title=Pancreatic adenocarcinoma. | journal=BMJ | year= 2012 | volume= 344 | issue= | pages= e2476 | pmid=22592847 | doi=10.1136/bmj.e2476 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22592847 }} </ref> <ref name="pmid22997452">{{cite journal| author=Seufferlein T, Bachet JB, Van Cutsem E, Rougier P, ESMO Guidelines Working Group| title=Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. | journal=Ann Oncol | year= 2012 | volume= 23 Suppl 7 | issue= | pages= vii33-40 | pmid=22997452 | doi=10.1093/annonc/mds224 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22997452 }} </ref> | ||
Revision as of 15:50, 21 November 2017
|
Pancreatic cancer Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Pancreatic cancer classification On the Web |
|
American Roentgen Ray Society Images of Pancreatic cancer classification |
|
Risk calculators and risk factors for Pancreatic cancer classification |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aravind Reddy Kothagadi M.B.B.S[2]
Overview
Pancreatic cancers can be classified based on the production of hormones into exocrine and endocrine cancers. Pancreatic exocrine tumors include different types such as Adenocarcinoma, acinar cell carcinoma, adenosquamous carcinoma and pancreatoblastomas. Pancreatic endocrine tumors include insulinomas, glucagonomas, VIPomas, somatostatinomas and ppomas.
Classification
Pancreatic cancers can be classified based on the production of hormones into exocrine and endocrine cancers:
- Types of Pancreatic Cancers:[1]
| Types of Pancreatic Cancers | |
|---|---|
| Pancreatic Exocrine Cancers | Pancreatic Endocrine Cancers (Pancreatic Neuroendocrine Tumours) |
|
|
|
|
|
|
- Types of Pancreatic Intraepithelial Neoplasia (PanIN):[1]
| Types of Pancreatic Intraepithelial Neoplasia (PanIN) |
|---|
| PanIN 1 (low grade) |
|
|
| PanIN 2 (intermediate grade) |
|
| PanIN 3 (high grade/carcinoma in situ) |
|
|
- Functional Pancreatic Neuroendocrine Tumors and their Characteristics are mentioned in the following table:[2]
| Functional Pancreatic Neuroendocrine Tumors and their Characteristics | |||
|---|---|---|---|
| Tumor type and syndrome | Location in pancreas | Signs and symptoms | Circulating biomarkers |
| Insulinoma (Whipple’s triad) |
|
|
|
| Gastrinoma (Zollinger–Ellison) |
|
|
|
| VIPoma (Verner– Morrison syndrome, WDHA) |
|
| |
| Glucagonoma |
| ||
| Somatostatinoma |
|
|
|
| Ppoma |
|
|
|
**Key
CgA- Chromogranin A
CgB- Chromogranin B
PP- Pancreatic polypeptide
| TNM Classification for Pancreatic Cancer: | |
|---|---|
| Primary tumor | |
| TX | Primary tumor cannot be assessed |
| T0 | No evidence of primary tumor |
| Tis | Carcinoma in situ |
| T1 | Tumor limited to the pancreas, ≤2 cm in greatest dimension |
| T2 | Tumor limited to the pancreas, >2 cm in greatest dimension |
| T3 | Tumor extends beyond the pancreas but without involvement of the celiac axis or the superior mesenteric artery |
| T4 | Tumor involves the celiac axis or the superior mesenteric artery (unresectable primary tumor) |
| Regional lymph nodes | |
| NX | Regional lymph nodes cannot be assessed |
| N0 | No regional lymph node metastasis |
| N1 | Regional lymph node metastasis |
| Distant metastases | |
| MX | Distant metastasis cannot be assessed |
| M0 | No distant metastasis |
| M1 | Distant metastasis |
Refrences
- ↑ 1.0 1.1 1.2 Bond-Smith G, Banga N, Hammond TM, Imber CJ (2012). "Pancreatic adenocarcinoma". BMJ. 344: e2476. doi:10.1136/bmj.e2476. PMID 22592847.
- ↑ Ryan DP, Hong TS, Bardeesy N (2014). "Pancreatic adenocarcinoma". N Engl J Med. 371 (11): 1039–49. doi:10.1056/NEJMra1404198. PMID 25207767.
- ↑ Seufferlein T, Bachet JB, Van Cutsem E, Rougier P, ESMO Guidelines Working Group (2012). "Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up". Ann Oncol. 23 Suppl 7: vii33–40. doi:10.1093/annonc/mds224. PMID 22997452.